HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
In this study, we will determine whether treating pregnant and breastfeeding women
co-infected with human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2
(HSV-2) with daily valacyclovir will reduce HIV-1 levels in plasma, genital, and breast milk
and will decrease the risk of mother-to-child HIV-1 transmission (MTCT).
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Puget Sound Partners for Global Health Royalty Research Fund - University of Washington